Title: SYSTEMIC DRUGS IN THE TREATMENT OF DERMATOPHYTOSES
Abstract: International Journal of DermatologyVolume 32, Issue 1 p. 16-21 SYSTEMIC DRUGS IN THE TREATMENT OF DERMATOPHYTOSES MATTHEW J. STILLER M.D., Corresponding Author MATTHEW J. STILLER M.D. From the Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, New York.Address for correspondence: Matthew J. Stiller, M.D., Ronald O. Perelman Department of Dermatology, NYU Medical Center, 550–560 First Avenue, New York, NY 10016.Search for more papers by this authorOMAR P. SANGUEZA M.D., OMAR P. SANGUEZA M.D. From the Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, New York.Search for more papers by this authorJEROME L. SHUPACK M.D., JEROME L. SHUPACK M.D. From the Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, New York.Search for more papers by this author MATTHEW J. STILLER M.D., Corresponding Author MATTHEW J. STILLER M.D. From the Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, New York.Address for correspondence: Matthew J. Stiller, M.D., Ronald O. Perelman Department of Dermatology, NYU Medical Center, 550–560 First Avenue, New York, NY 10016.Search for more papers by this authorOMAR P. SANGUEZA M.D., OMAR P. SANGUEZA M.D. From the Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, New York.Search for more papers by this authorJEROME L. SHUPACK M.D., JEROME L. SHUPACK M.D. From the Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, New York.Search for more papers by this author First published: January 1993 https://doi.org/10.1111/j.1365-4362.1993.tb00952.xCitations: 21AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Lesher, JL, Smith, JG. Antifungal agents in dermatology. J Am Acad Dermatol 1987; 17: 383–393. 2 Hay, RJ. Antifungal drugs in dermatology. Semin Dermatol 1990; 9: 309–317. 3 Hay, RJ. The current status of antimycotics in the treatment of local mycoses. Acta Derm Venereol (Stockh) 1986; 5121: 103–108. 4 Araujo, OE, Flowers, FP, King, MM. Griseofulvin: a new look at an old drug. DICP 1990; 24: 851–854. 5 Faergemann, J, Maibach, H. Griseofulvin and ketoconazole in dermatology. Semin Dermatol 1983; 2: 262–269. 6 Becker, LE. Griseofulvin. Dermatol Clin 1984; 2: 115–120. 7 Blank, H. Commentary: treatment of dermatomycoses with griseofulvin. Arch Dermatol 1982; 118: 834–836. 8 Straughn, AB, Meyer, MC, Raghow, G, et al. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J Pharmacokinet Biopharm 1980; 8: 347–362. 9 Artis, WM, Odle, BM, Jones, HE. Griseofulvin resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117: 16–19. 10 Robinson, DCV, Ferciot, TN, Robinson, HM. hi vitro resistance studies with griseofulvin. Arch Dermatol 1960; 81: 681–683. 11 Osment, LS. The many effects of griseofulvin. Ala J Med Sci 1969; 6: 392–398. 12 Levin, HB, Alden, HS, Ajello, L. Use of griseofulvin in office practice. Arch Dermatol 1960; 81: 827–832. 13 Bickers, DR, Hazen, PG, Lynch, WS. Clinical pharmacology of skin disease. New York : Churchill Livingstone, 1984: 163. 14 Fromtling, RA. Overview of medically important antifungal azoles. Clin Microbiol Rev 1988; 1: 187–217. 15 Cleary, JD, Taylor, JW, Chapman, SW. Imidazoles and triazoles in antifungal therapy. DICP 1990; 24: 148–151. 16 Sud, IJ, Feingold, DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol 1981; 76: 438–441. 17 Daneshmend, TK, Warnock, DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13–34. 18 Odds, FC, Milne, LJRR, Gentles, JC, et al. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother 1980; 6: 97–104. 19 Welsh, O, Rodriguez, M. Treatment of dermatomycoses with ketoconazole. Rev Infect Dis 1980; 2: 582–585. 20 Cox, FW, Stiller, RL, South, DA. Oral ketoconazole for dermatophyte infections. J Am Acad Dermatol 1982; 6: 455–462. 21 Heeres, J, Backx, LJJ, Mostmans, JH, et al. Antimycotic imidazoles, part 4, synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 1979; 22: 1003–1005. 22 Hay, RJ, Clayton, YM, Griffiths, WAD, et al. A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis. Br J Dermatol 1985; 112: 691–696. 23 Wishart, JM. A double blind trial of ketoconazole versus griseofulvin treatment for dermatophyte infections. Aust J Dermatol 1983; 24: 40–43. 24 Legendre, R, Steltz, M. A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes. Rev Infect Dis 1980; 2: 582–585. 25 Defelice, R, Johnson, DG, Galgiani, JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981; 19: 1073–1074. 26 Pont, A, Williams, PL, Loose, DS, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982; 97: 370–372. 27 Pont, A, Williams, PL, Azhar, S, et al. Ketoconazole impairs testosterone synthesis. Arch Intern Med 1982; 142: 2137–2140. 28 Lewis, JH, Zimmerman, HJ, Benson, GD, et al. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984; 86: 503–513. 29 Lake-Bakaar, G, Scheuer, PJ, Sherlock, S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ 1987; 294: 419–422. 30 Jacobs, PH. Treatment of fungal skin infections: state of the art. J Am Acad Dermatol 1990; 23: 549–551. 31 Rippon, JW. A new era in antimycotic agents. Arch Dermatol 1986; 122: 399–402. 32 Davey, PG. New antiviral and antifungal drugs. BMJ 1990; 300: 793–798. 33 Roberts, DT. Itraconazole in dermatology. J Dermatol Treat 1992; 2: 155–158. 34 Cauwenbergh, G, DeGreef, H, Heykants, J. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263–268. 35 RT Hay, JR Graybill, B Dupont, (eds). The First International Symposium on Itraconazole. Rev Infect Dis 1987; 9: S1–S146. 36 Saul, A, Bonifaz, A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 1990; 23: 554–558. 37 Hay, RJ, Clayton, YM, Moore, MK, et al. Itraconazole in the management of chronic dermatophytosis. J Am Acad Dermatol 1990; 23: 561–564. 38 Rongioletti, F, Robert, E, Tripod, S, et al. Treatment of onychomycosis with itraconazole. J Dermatol Treat 1992; 2: 145–146. 39 Hay, RJ, Clayton, YM, Moore, MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359–366. 40 Walsoe, I, Stangerup, M, Svejgaard, E. Itraconazole in onychomycosis: open and double-blind studies. Acta Derm Venereol (Stockh) 1990; 70: 137–140. 41 Grant, SM, Clissold, SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310–344. 42 Medoff, G, Kobayashi, GS. Systemic fungal infections: an overview. Hosp Pract 1991; 26: 41–52. 43 Hay, RJ. New oral therapies for dermatophytosis. Ann NY Acad Sci 1988; 544: 580–586. 44 Notowicz, A, Koster, M. Itraconazole versus griseofulvin. A double-blind comparison in patients with tinea corporis and cruris. J Dermatol Treat 1992; 3: 23–25. 45 Gagliani, JN. Fluconazole, a new antifungal agent. Ann Intern Med 1990; 113: 177–179. 46 Dupont, B, Drouhet, E. Fluconazole for the treatment of fungal disease in the immunosuppressed patient. Ann NY Acad Sci 1988; 544: 564–570. 47 Birnbaum, JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 782–785. 48 Ryder, NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98–100. 49 Kagawa, S. Clinical efficacy of terbinafine in 629 Japanese patients with dermaromycosis. Clin Exp Dermatol 1989; 14: 114–115. 50 Jensen, JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989; 114: 110–113. 51 Villars, V, Jones, TC. Clinical efficacy and tolerability of terbinafine (Lamisil)-a new topical and systemic fungicidal drug for treatment of dermatomycosis. Clin Exp Dermatol 1989; 14: 124–127. 52 Savin, RC, Zaias, N. Treatment of chronic moccasin type pedis with terbinafine: a double-blind, placebo-controlled trial. J Am Acad Dermatol 1990; 23: 804–806. 53 Savin, R. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). Clin Exp Dermatol 1989; 14: 116–119. 54 Zaias, N, Serrano, L. The successful treatment of finger Trichophyton rubnim onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120–123. 55 Zaias, N. Management of onychomycosis with oral terbinafine. J Am Acad Dermatol 1990; 23: 810–812. 56 Savin, RC. Oral terbinafine vs. griseofulvin in the treatment of moccasin-type tinea pedis. J Am Acad Dermatol 1990; 23: 807–809. 57 Rosenthal, SA. Unpublished communication. Citing Literature Volume32, Issue1January 1993Pages 16-21 ReferencesRelatedInformation
Publication Year: 1993
Publication Date: 1993-01-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 25
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot